拉米诺病的代谢失调:对心力衰竭和心脏健康的影响
T Torfs1, R J A Veltrop2,3,4,5,6, G Lezzoche1
1Department of Cardiology, CARIM Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.
Current heart failure reports
|February 2, 2026
概括
细膜病,影响核膜蛋白的遗传疾病,通过代谢失调引起心力衰竭. 针对这些代谢途径显示出改善受影响个体心脏健康的前景.
科学领域:
- 心血管医学 心血管医学
- 遗传学 遗传学 是一个
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 拉米诺病是一种由核膜蛋白变体引起的遗传性疾病.
- 心力衰竭是拉米诺病患者发病率和死亡率的重要原因.
- 向代谢视角的转变对于理解层层病变至关重要.
研究的目的:
- 阐明在拉米诺病症中代谢失调的分子机制.
- 探索新陈代谢变化对心脏健康的影响.
- 将不同的临床表型与一系列代谢观测联系起来.
主要方法:
- 审查新出现的证据,将A型薄膜与细胞代谢联系起来.
- 对LMNA变异对基因调节的分子机制的分析.
- 检查心脏症状之前的代谢变化.
主要成果:
- 系统性代谢变化 (脂质变,胰岛素耐药性,高甘油三血症) 在拉米诺病患者的心脏症状之前.
- LMNA变种破坏脂肪酸,葡萄糖利用和线粒体基因调节.
- 代谢失调促进心肌细胞纤维化和亡,增加心脏敏感性.
结论:
- 代谢失调是整个拉米诺病谱的一致特征.
- 准代谢途径为改善心脏结果提供了临床前的前景.
- 了解代谢变化是管理心脏并发症的关键.
相关概念视频
Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction
886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
Heart Failure VI: Adjunct Therapies
340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
Heart Failure V: Medical Management
319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319


